☆ 4.5 Article

Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology

EUROPEAN JOURNAL OF HEART FAILURE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Editorial Material Cardiac & Cardiovascular Systems

Assessing and treating congestion in acute decompensated heart failure: are we seeing the light at the end of the tunnel?

Alexandre Mebazaa et al.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial

Joan Carles Trullas et al.

Summary: This study aims to evaluate whether adding hydrochlorothiazide (HCTZ) to intravenous furosemide is a safe and effective strategy for improving diuretic response in acute heart failure (AHF). The study found that adding HCTZ to loop diuretic therapy can improve diuretic response in patients with AHF, but may also lead to renal function impairment.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Use of patient-reported outcomes in heart failure: from clinical trials to routine practice

Gianluigi Savarese et al.

Summary: Heart failure is a complex syndrome that significantly impairs multiple aspects of daily activities and reduces the overall quality of life. Historically, the assessment of disease status and symptom severity has been solely based on physician evaluation, neglecting the patient's experience. Patient-reported outcomes (PROs) aim to shift towards a more patient-centered approach by involving patients in their own care. While PROs have shown precision in evaluating disease status and predicting prognosis in randomized controlled trials, their implementation in clinical practice remains limited. This review discusses the use of PROs in heart failure, the most commonly used PROs, their application in trials, and the potential for integrating PROs into routine clinical practice. By exploring the advantages, disadvantages, and strategies to promote their use, this review aims to encourage the systematic inclusion of the patient's perspective in heart failure care.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes

Danielle M. M. Gualandro et al.

Summary: The study aims to assess the incidence, phenotypes, determinants, and outcomes of primary acute heart failure (AHF) following non-cardiac surgery. The study found that the incidence of postoperative AHF was 2.5%, with 51% occurring in patients without known heart failure and 49% in patients with chronic heart failure. Patients with pAHF had significantly higher all-cause mortality and AHF readmission within 1 year than patients without pAHF.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

添加到收藏夹

Article Medicine, General & Internal

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure The TRANSFORM-HF Randomized Clinical Trial

Robert J. Mentz et al.

Summary: A randomized trial found that torsemide did not result in a significant difference in all-cause mortality compared with furosemide among patients hospitalized for heart failure. However, the interpretation of these findings is limited by loss to follow-up and participant crossover and nonadherence.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Practical Patient Care Considerations With Use of Vericiguat After Worsening Heart Failure Events

Vishal N. Rao et al.

Summary: Vericiguat is a recommended therapy for reducing morbidity and mortality in patients with worsening chronic heart failure. However, there are potential barriers to its prescription, such as lack of familiarity among providers and concerns about adverse effects. This review provides an overview of vericiguat therapy, proposes a guidance strategy, and summarizes patient counseling points.

JOURNAL OF CARDIAC FAILURE (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Worsening Heart Failure: Nomenclature, Epidemiology, and Future Directions JACC Review Topic of the Week

Stephen J. Greene et al.

Summary: Heart failure (HF) is a progressive disease with periods of stability interrupted by worsening HF (WHF) episodes. The definition of WHF has evolved to include events outside of hospitalization. While most HF clinical trials focus on hospitalization and death, recent studies are investigating WHF regardless of care location. This article reviews the evolving definition of WHF, emphasizes its importance as a new phase in HF, summarizes recent clinical trials on novel therapies, and outlines unmet needs in WHF identification and treatment.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Trial of an Intervention to Improve Acute Heart Failure Outcomes

D. S. Lee et al.

Summary: The use of a hospital-based strategy to support clinical decision making and rapid follow-up for patients with acute heart failure led to a lower risk of death and hospitalization for cardiovascular causes within 30 days compared to usual care.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Frailty and Effects of a Multidomain Physical Rehabilitation Intervention Among Older Patients Hospitalized for Acute Heart Failure A Secondary Analysis of a Randomized Clinical Trial

Ambarish Pandey et al.

Summary: Frailty is common among older patients with ADHF and is associated with worse QOL and higher risk of clinical events. The REHAB-HF trial showed that a 3-month tailored physical rehabilitation intervention improved physical function and QOL for these patients. This analysis found that patients with worse baseline frailty had a more significant improvement in physical function with the intervention compared to those who were prefrail.

JAMA CARDIOLOGY (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Albuminuria as a marker of systemic congestion in patients with heart failure

Eva M. Boorsma et al.

Summary: Albuminuria is common in patients with heart failure and is associated with clinical symptoms and biomarkers of congestion. It is also related to the severity and prognosis of heart failure.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial

Jan Biegus et al.

Summary: This study evaluated the decongestion effects of empagliflozin in patients with acute heart failure (AHF) and found that compared to placebo, empagliflozin significantly reduced markers of decongestion at all time-points. Patients with greater weight loss within the first 15 days showed higher clinical benefit at Day 90.

EUROPEAN HEART JOURNAL (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Inotropic therapy in patients with advanced heart failure. A clinical consensus statement from the Heart Failure Association of the European Society of Cardiology

Finn Gustafsson et al.

Summary: This article reviews the clinical consensus on the use of inotropic support in patients with advanced heart failure. Current guidelines recommend inotropic use only in cases of acute decompensated heart failure with organ malperfusion or shock. However, inotropic support may be justified in other cases of advanced heart failure without severe acute decompensation. The article examines the clinical evidence supporting the use of inotropes in these situations, including patients with persistent congestion, systemic hypoperfusion, or advanced heart failure requiring palliation, and those undergoing left ventricular assist device implantation or heart transplantation.

EUROPEAN JOURNAL OF HEART FAILURE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Rationale, Design and Baseline Characteristics of the PARAGLIDE-HF Trial: Sacubitril/Valsartan vs Valsartan in HFmrEF and HFpEF With a Worsening Heart Failure Event

Robert J. Mentz et al.

Summary: The PARAGON-HF trial evaluated the effects of Sac/Val compared to Val on clinical outcomes in patients with HFpEF or HFmrEF. The PARAGLIDE-HF trial further investigated the use of Sac/Val in patients with recent worsening HF events and in specific populations not well represented in the PARAGON-HF trial, including those with de novo HF, severe obesity, and Black patients.

JOURNAL OF CARDIAC FAILURE (2023)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Transcatheter interventions for heart failure

Azeem Latib et al.

Summary: Despite advancements in medical management, heart failure still causes significant morbidity and mortality. More research is needed to develop additional modalities for treatment and management, reducing hospitalizations and improving patient quality of life. Non-valvular catheter-based therapies have rapidly emerged in the last decade to address key processes in heart failure progression, such as ventricular remodeling, neurohumoral activation, and congestion. This review examines the current stage of development for these procedures.

EUROINTERVENTION (2023)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Global burden of heart failure: a comprehensive and updated review of epidemiology

Gianluigi Savarese et al.

Summary: Heart Failure (HF) is a multi-faceted and life-threatening syndrome with significant morbidity and mortality worldwide, affecting over 64 million people. While the incidence of HF has stabilized in industrialized countries, the prevalence is increasing due to population ageing and improved treatment. Developing countries lack substantial data on HF epidemiology, which shows different features compared to the Western world. This review provides updated estimates on global burden of HF including prevalence, incidence, outcomes, and costs.

CARDIOVASCULAR RESEARCH (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

Theresa A. McDonagh et al.

Summary: All experts involved in the development of the guidelines have declared their interests, and the declarations have been compiled and published in a supplementary report. The report can be accessed on the ESC website. The supplementary data provide background information and detailed discussion of the data that form the basis for the guidelines.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry

Jasper Tromp et al.

Summary: This study found differences in precipitants leading to hospitalizations for acute heart failure (AHF) on a global scale, highlighting potential regional differences in targeted prevention strategies and identifying high-risk patients for early mortality.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

In-hospital initiation of quadruple medical therapy for heart failure: making the post-discharge vulnerable phase far less vulnerable

Stephen J. Greene et al.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction

Daniela Tomasoni et al.

Summary: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are recommended for the treatment of heart failure patients due to their favorable effects. These drugs can be administered early in the treatment process to reduce clinical events and improve quality of life, and their efficacy is independent of background therapy.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Worsening renal function in acute heart failure in the context of diuretic response

Johanna E. Emmens et al.

Summary: In two large cohorts of patients with acute heart failure (AHF), the occurrence of worsening renal function (WRF) in the first 4 days was not associated with worse outcomes when patients had a good diuretic response. The interaction between diuretic response and WRF should be considered in the management of AHF patients.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry

Agnieszka Kaplon-Cieslicka et al.

Summary: This study provides a comprehensive characterization of acute heart failure with preserved, mildly reduced, and reduced ejection fraction. The results show differences in hospitalization reasons, characteristics, treatment, and post-discharge risks among the three types.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Emergency Department Visits Versus Hospital Readmissions Among Patients Hospitalized for Heart Failure

Anand Shah et al.

Summary: The predictors and clinical significance of managing worsening heart failure in outpatient or emergency department settings instead of hospitalization are unclear. This study found that worse renal function and prior hospitalization for heart failure were associated with a higher likelihood of early postdischarge readmission, while patients discharged from the emergency department had significantly lower mortality risk compared to readmitted patients.

JOURNAL OF CARDIAC FAILURE (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

Subodh Verma et al.

Summary: This study analyzed the efficacy and safety of empagliflozin in patients with heart failure with reduced ejection fraction in addition to background foundational treatments. The results showed that empagliflozin reduced the risk of cardiovascular death and heart failure hospitalization, as well as total heart failure hospital admissions, regardless of background therapy or medication doses. Empagliflozin was well tolerated across all subgroups of patients.

LANCET DIABETES & ENDOCRINOLOGY (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Practical outpatient management of worsening chronic heart failure

Nicolas Girerd et al.

Summary: Traditionally, the management of worsening heart failure has been hospital-based, but with the increasing burden of the disease, a different strategy is needed. Outpatient intravenous diuretic treatment has been developed in the US, while European centers still prefer in-hospital management. Embracing novel outpatient approaches can reduce the burden on healthcare systems and improve patient satisfaction. This article provides essential knowledge and practical guidelines for implementing these new approaches.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology

Wilfried Mullens et al.

Summary: Novel pharmacologic treatment options reduce mortality and morbidity in patients with heart failure, despite the concerns about potential risks to renal function. These treatments have been shown to be beneficial even in patients with poor renal function.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Defining changes in physical limitation from the patient perspective: insights from the VITALITY-HFpEF randomized trial

Javed Butler et al.

Summary: This study aimed to estimate meaningful thresholds for improvement or worsening in the Kansas City Cardiomyopathy Questionnaire (KCCQ) physical limitation score (PLS) in patients with heart failure and preserved ejection fraction (HFpEF). Using anchor- and distribution-based approaches, the study found that a change of >= 8.33 points in KCCQ-PLS may represent the minimal clinically important difference for improvement, while a change of <= -4.17 points may suggest deterioration in patients with HFpEF.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Adriaan A. Voors et al.

Summary: The sodium-glucose cotransporter 2 inhibitor empagliflozin improves clinical outcomes in patients hospitalized for acute heart failure, regardless of ejection fraction or the presence of diabetes.

NATURE MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Intervention Adherence in REHAB-HF: Predictors and Relationship With Physical Function, Quality of Life, and Clinical Events

M. Benjamin Nelson et al.

Summary: The study demonstrates that adherence to a rehabilitation intervention plan is significantly associated with improved patient-centered and clinical event outcomes in older, frail patients with acute decompensated heart failure.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognostic Implications of N-Terminal Pro-B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved

James L. Januzzi et al.

Summary: In this study, the associations between NT-proBNP and hscTnT biomarkers and clinical outcomes in heart failure patients were evaluated. Higher baseline NT-proBNP and hs-cTnT concentrations were associated with more comorbidities and worse heart failure severity. Empagliflozin treatment consistently reduced the risk for cardiovascular events and reduced the decline of eGFR across different levels of NT-proBNP and hs-cTnT. Furthermore, empagliflozin modestly lowered NT-proBNP levels.

JACC-HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Aiming at harmony. Comparing and contrasting International HFrEF Guidelines

Daniela Tomasoni et al.

Summary: Large randomized controlled trials have led to significant changes in the treatment of heart failure patients with reduced left ventricular ejection fraction (HFrEF). The recent guidelines issued by the European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association/Heart Failure Society of America (ACC/AHA/HFSA) recommend the use of four classes of drugs to reduce cardiovascular death and HF hospitalizations. There are minor differences but many consistent recommendations between the two guidelines.

EUROPEAN HEART JOURNAL SUPPLEMENTS (2022)

添加到收藏夹

Article Medicine, General & Internal

Safety, tolerability, and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial

Alexandre Mebazaa et al.

Summary: This study aimed to investigate the impact of guideline-directed medical therapy dose and up-titration pace on the efficacy and safety of patients admitted to the hospital for acute heart failure. The results showed that compared with usual care, high-intensity care significantly reduced the risk of heart failure readmission or all-cause death within 180 days.

LANCET (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial

Marco Metra et al.

Summary: In the AFFIRM-AHF study, intravenous ferric carboxymaltose (FCM) was found to reduce heart failure hospitalizations and cardiovascular deaths in patients with ischemic HF but not in those with non-ischemic HF. FCM also showed a nominal improvement in quality of life. Further studies are needed to assess the impact of etiology on FCM efficacy.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial

Safia Chatur et al.

Summary: Worsening renal function may impact long-term outcomes in heart failure (HF). This study found that HF hospitalization denotes increased risk for kidney disease progression, and the trajectories of renal function change before and after hospitalization.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand

Saranya Hariharaputhiran et al.

Summary: This study investigated the long-term survival rate of patients hospitalized for heart failure, identified predictors of survival and estimated the decrease in life expectancy. The study found that less than one in five patients survived after 10 years, and patients experienced a nearly 60% decrease in life expectancy compared to the general population, highlighting the significant societal burden of heart failure.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Analysis of Worsening Heart Failure Events in an Integrated Health Care System

Andrew P. Ambrosy et al.

Summary: The study aims to describe the incidence of worsening heart failure (WHF) events across the care continuum from ambulatory encounters to hospitalizations.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF

Javed Butler et al.

Summary: This study establishes meaningful thresholds for patient-reported outcomes measures in heart failure patients and identifies the minimal clinically important difference in KCCQ-TSS for both HFrEF and HFpEF patients.

JACC-HEART FAILURE (2022)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction

Wassim Bedrouni et al.

CIRCULATION-HEART FAILURE (2022)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Worsening renal function precedes and follows worsening heart failure

Nicolas Girerd

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Congestion in heart failure: a circulating biomarker-based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

Julio Nunez et al.

Summary: Congestion is a significant symptom of heart failure and it varies in different types of heart failure. This article discusses the classification of heart failure based on congestion characteristics and the utility of circulating biomarkers for assessing and managing fluid overload. Further studies are needed to determine the effectiveness of biomarkers in addition to clinical evaluation, haemodynamics, and imaging.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Device-based remote monitoring strategies for congestion-guided management of patients with heart failure: a systematic review and meta-analysis

Andrea Zito et al.

Summary: This study aimed to evaluate whether device-based remote monitoring strategies guided by congestion markers are more effective than standard therapy for the management of worsening heart failure (HF). The findings showed that a haemodynamic-guided strategy was associated with a reduced risk of all-cause death and HF hospitalizations, while an impedance-guided strategy did not provide significant benefits.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum

Javed Butler et al.

Summary: Patients with heart failure with reduced ejection fraction (HFrEF) have a high residual risk of adverse outcomes. Soluble guanylate cyclase (sGC) stimulators, such as vericiguat, may have the potential to lower this risk. However, further research is needed to evaluate the effects of vericiguat in low-risk HFrEF patients.

EUROPEAN JOURNAL OF HEART FAILURE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction

Jonathan W. Cunningham et al.

Summary: This study investigates the clinical outcomes and response to dapagliflozin in patients with HF, finding that dapagliflozin safely reduces the risk of worsening HF or cardiovascular death in patients recently hospitalized for HF.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

S. D. Solomon et al.

Summary: The study shows that SGLT2 inhibitors are effective in reducing the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. However, whether they are effective in patients with a higher left ventricular ejection fraction remains uncertain.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Acetazolamide in Acute Decompensated Heart Failure with Volume Overload

Wilfried Mullens et al.

Summary: The addition of acetazolamide to loop diuretic therapy in patients with acute decompensated heart failure results in a higher incidence of successful decongestion without increasing adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction The EMPEROR-Reduced Trial

Milton Packer et al.

Summary: Empagliflozin reduces the risk and total number of worsening heart failure events in patients with heart failure and reduced ejection fraction, with benefits seen early after treatment initiation and sustained throughout the therapy.

CIRCULATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study

Johanna Koehler et al.

Summary: Telemedical care in patients with CHF and moderate depression not only improved depressive symptoms, but also had a positive influence on quality of life compared to usual care. Adjustment was made for various factors to confirm the effect of telemonitoring on depressive symptoms.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand

Clementine Labrosciano et al.

Summary: The study found variations in 30-day mortality and readmission rates after heart failure hospitalisations in Australia and New Zealand, with a significant decline in mortality rates and a modest decrease in readmission rates over the study period.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

Milton Packer et al.

Summary: The combination treatment of sacubitril/valsartan and empagliflozin in heart failure patients has been shown to reduce cardiovascular death or hospitalization risk, maintain stable glomerular filtration rate, and the effects are not diminished by intensive treatment.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades

Antoine Kimmoun et al.

Summary: This study analyzed AHF studies with more than 100 patients from 1980 to 2017 and found a declining trend in 30-day all-cause death rates, although mortality and readmission rates remained high. The increase in the use of oral neurohormonal antagonists may be associated with improved survival after AHF episodes.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Ultrasound imaging of congestion in heart failure: examinations beyond the heart

Pierpaolo Pellicori et al.

Summary: Ultrasound methods play a critical role in detecting and quantifying congestion in patients with heart failure, enabling earlier and more accurate diagnosis and facilitating treatment strategies.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Is acute heart failure a distinctive disorder? An analysis from BIOSTAT-CHF

Beth A. Davison et al.

Summary: This retrospective analysis aimed to identify markers that could distinguish between acute heart failure (HF) and worsening HF in chronic outpatients. It found that acute HF patients had higher morbidity and mortality compared to outpatients with chronic HF developing worsening HF. The study suggests that the identified markers may be useful in diagnosing acute HF more effectively and could potentially be targeted for treatment development.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry

Muhammad Shahzeb Khan et al.

Summary: In this study involving 3426 US outpatients with chronic heart failure, one in four patients received outpatient escalation of diuretic therapy, which was associated with signs/symptoms of congestion. Any degree of outpatient diuretic dose escalation was linked to heart failure hospitalizations and resource utilization, but not with all-cause mortality.

CIRCULATION-HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Head-to-head comparison of contemporary heart failure risk scores

Pau Codina et al.

Summary: Multiple heart failure risk scores were compared in terms of their discrimination and overall performance, with BCN-Bio-HF calculator showing the best results in discrimination and overall performance, while MAGGIC-HF displayed the best calibration. Regular updating and recalibration of these online calculators are necessary to enhance their accuracy as heart failure management progresses rapidly.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

Deepak L. Bhatt et al.

Summary: In patients with diabetes and recent worsening heart failure, treatment with sotagliflozin significantly reduced the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure compared to placebo, regardless of the timing of administration.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction

Vishal N. Rao et al.

Summary: SGLT-2 inhibitor therapy is well suited for initiation during heart failure hospitalization, with rapid clinical benefits and minimal risk. Delaying initiation to the outpatient setting may increase early postdischarge risks.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Biykem Bozkurt et al.

Summary: This document proposes a universal definition of heart failure as a clinical syndrome and revised stages of HF, as well as a new classification based on left ventricular ejection fraction (LVEF) levels. The classification includes HFrEF, HFmrEF, HFpEF, and HFimpEF based on LVEF percentages.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019

Petar M. Seferovic et al.

Summary: The HFA Atlas survey revealed significant heterogeneity in HF disease burden, management resources, and data quality across ESC member countries, highlighting the importance of a systematic approach to capturing HF statistics for quantifying and addressing inequalities and improvements in care.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Patients Hospitalized for De Novo Versus Worsening Chronic Heart Failure in the United States

Stephen J. Greene et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017

Manyoo A. Agarwal et al.

Summary: This study found that the hospitalization rates for heart failure in US adults declined from 4.4 in 2010 to 4.1 in 2013, and then increased from 4.2 in 2014 to 4.9 in 2017. Similarly, readmission rates after index hospitalizations followed a similar trend. Future studies are needed to validate these findings and improve policies for heart failure management.

JAMA CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

David D. Berg et al.

Summary: The study showed that treatment with dapagliflozin can rapidly reduce the risk of cardiovascular death or worsening heart failure, with patients who had recent HF hospitalization experiencing greater relative and absolute risk reductions with dapagliflozin.

JAMA CARDIOLOGY (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations

Marat Fudim et al.

Summary: Volume recruitment from the splanchnic compartment is a crucial physiological response to stressors such as physical activity and blood loss. Excess fluid redistribution from this compartment in heart failure patients can lead to increased cardiac filling pressures and reduced exercise capacity. Blocking neural activity of the greater splanchnic nerve may provide significant benefits in some heart failure patients, but the long-term safety of splanchnic nerve modulation therapy remains unknown.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Worsening Heart Failure Episodes Outside a Hospital Setting in Heart Failure With Preserved Ejection Fraction The PARAGON-HF Trial

Muthiah Vaduganathan et al.

Summary: This study evaluated the frequency and prognostic implications of urgent heart failure visits in patients with HFpEF. Urgent ambulatory HF visits requiring intravenous diuretic treatment were found to have similar prognostic importance as HF hospitalizations in HFpEF patients. The inclusion of urgent HF visits in a prespecified composite endpoint reinforced the treatment efficacy of sacubitril/valsartan compared with valsartan in the clinical trial.

JACC-HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction EMPEROR-Preserved Trial

Milton Packer et al.

Summary: Empagliflozin significantly reduced the risk of heart failure-related inpatient and outpatient events in patients with heart failure with preserved ejection fraction, including cardiovascular death, heart failure hospitalization, and urgent visits, while also decreasing total heart failure hospitalizations and intensive care admissions. Patients receiving empagliflozin may experience improved New York Heart Association functional class levels.

CIRCULATION (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC)

Wouter C. Meijers et al.

Summary: This review examined the most promising emerging biomarkers for the clinical assessment and management of patients with heart failure, including high-sensitivity cardiac troponins, procalcitonin, novel kidney markers, sST2, galectin-3, GDF-15, CD146, neprilysin, and ADM. Analytical considerations, diagnostic and prognostic performance, potential implementation in clinical algorithms, and ongoing clinical trials were discussed for each biomarker.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF

Matteo Pagnesi et al.

Summary: The study found that moderate-severe mitral regurgitation is common in patients with worsening chronic or new-onset acute heart failure and is strongly associated with outcome, independently of other features related to heart failure severity.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review

Julio Nunez et al.

Summary: CA125 is a reliable marker for congestion and inflammation in heart failure patients, strongly associated with a higher risk of adverse clinical events and potential for guiding decongestive therapy following acute heart failure events. Further research is needed to better understand its biological role and utility in clinical practice.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial

Jr James L. Januzzi et al.

Summary: This study found that empagliflozin treatment reduced the risk of heart failure or renal events regardless of baseline NT-proBNP concentration in patients with heart failure.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

JoAnn Lindenfeld et al.

Summary: The study aimed to evaluate whether haemodynamic-guided management of heart failure is applicable to patients with different severity of symptoms (NYHA functional class II-IV). The overall study analysis showed that haemodynamic-guided management did not reduce the mortality rate and heart failure events in heart failure patients. However, a pre-COVID-19 impact analysis suggested a potential benefit of haemodynamic-guided management for heart failure patients, primarily by lowering the heart failure hospitalisation rate.

LANCET (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

To master heart failure, first master congestion

John G. F. Cleland et al.

LANCET (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event Insights From the VICTORIA Trial

Carolyn S. P. Lam et al.

Summary: This study analyzed patients at different time periods after heart failure hospitalization and found that patients closer to their index heart failure event had a higher risk of cardiovascular death or recurrent heart failure. Vericiguat reduced the risk of the primary outcome in all subgroups and showed a trend of greater benefit with longer time since the heart failure event.

JAMA CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Ewa A. Jankowska et al.

Summary: Patients with heart failure and iron deficiency experience poor health-related quality of life. Treatment with intravenous ferric carboxymaltose results in clinically beneficial effects on HRQoL as early as 4 weeks after treatment initiation, lasting up to 24 weeks.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

Biykem Bozkurt et al.

Summary: This document proposes a universal definition, revised stages, and new classification of heart failure based on left ventricular ejection fraction. The classification includes HF with reduced, mildly reduced, preserved, and improved ejection fraction, each with specific LVEF thresholds.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Analysis of Worsening Heart Failure Events in an Integrated Health Care System br

Andrew P. Ambrosy et al.

Summary: The study found that the incidence of worsening heart failure events has been increasing over the past decade, with outpatient encounters and emergency department visits/observation stays accounting for approximately half of the events and driving the overall growth in heart failure morbidity, indicating a poor short-term prognosis for patients.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Ewa A. Jankowska et al.

Summary: The study showed that in iron-deficient patients who had stabilized after an episode of acute heart failure, treatment with IV FCM resulted in significant beneficial effects on HRQoL, lasting up to 24 weeks.

EUROPEAN HEART JOURNAL (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Effects of Starting Doses of Enalapril in Patients with Chronic Heart Failure in the SOLVD Treatment Trial

Phillip H. Lam et al.

AMERICAN JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction

Julio Nunez et al.

AMERICAN JOURNAL OF MEDICINE (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Ambulatory Treatment of Worsening Heart Failure With Intravenous Loop Diuretics: A Four-Year Experience

Leo F. Buckley et al.

JOURNAL OF CARDIAC FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Evaluation of kidney function throughout the heart failure trajectory - a position statement from the Heart Failure Association of the European Society of Cardiology

Wilfried Mullens et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology

Jelena Celutkiene et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Comparing the Benefit of Novel Therapies Across Clinical Trials Insights From the VICTORIA Trial

Javed Butler et al.

CIRCULATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy

Kieran F. Docherty et al.

EUROPEAN HEART JOURNAL (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort

Jawad H. Butt et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Telemonitoring versus standard care in heart failure: a randomised multicentre trial

Michel Galinier et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Decreases in acute heart failure hospitalizations duringCOVID-19

Zachary L. Cox et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-in-human study

Wilfried Mullens et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Acute heart failure: More questions than answers

Daniela Tomasoni et al.

PROGRESS IN CARDIOVASCULAR DISEASES (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Role of CA125 in Worsening Heart Failure A BIOSTAT-CHF Study Subanalysis

Julio Nunez et al.

JACC-HEART FAILURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Paul W. Armstrong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark A Nationwide Cohort Study

Charlotte Andersson et al.

CIRCULATION-HEART FAILURE (2020)

添加到收藏夹

Letter Cardiac & Cardiovascular Systems

Implications of serial measurements of natriuretic peptides in heart failure: insights from BIOSTAT-CHF

Muhammad Zubair Israr et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Reduced rate of hospital presentations for heart failure during the Covid-19 pandemic in Toronto, Canada

Claudia Frankfurter et al.

CANADIAN JOURNAL OF CARDIOLOGY (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

One-Year Mortality After Intensification of Outpatient Diuretic Therapy

Christian Madelaire et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction A Prespecified Analysis of DAPA-HF

Kieran F. Docherty et al.

CIRCULATION (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Temporal trends in decompensated heart failure and outcomes duringCOVID-19: a multisite report from heart failure referral centres inLondon

Antonio Cannata et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network

Sebastian Koenig et al.

EUROPEAN JOURNAL OF HEART FAILURE (2020)

添加到收藏夹

Article Medicine, General & Internal

Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

Piotr Ponikowski et al.

LANCET (2020)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prevalence, pattern and clinical relevance of ultrasound indices of congestion in outpatients with heart failure

Pierpaolo Pellicori et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure

Jozine M. ter Maaten et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

John J. McMurray et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction

Javed Butler et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry

Ovidiu Chioncel et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Exercise Intolerance in Patients With Heart Failure

Marco Giuseppe Del Buono et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations

Christian Mueller et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Public, Environmental & Occupational Health

20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study

Claire A. Lawson et al.

LANCET PUBLIC HEALTH (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology

Wilfried Mullens et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study

Joao Pedro Ferreira et al.

EUROPEAN JOURNAL OF HEART FAILURE (2019)

添加到收藏夹

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure

Eric J. Velazquez et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion

Lucas N. L. Van Aelst et al.

EUROPEAN JOURNAL OF HEART FAILURE (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology

Maria G. Crespo-Leiro et al.

EUROPEAN JOURNAL OF HEART FAILURE (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey

Nicolas Girerd et al.

JACC-HEART FAILURE (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure

Nisha A. Gilotra et al.

JACC-HEART FAILURE (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Outpatient Worsening Heart Failure as a Target for Therapy A Review

Stephen J. Greene et al.

JAMA CARDIOLOGY (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?)

Susan Stienen et al.

CIRCULATION (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF

Marat Fudim et al.

EUROPEAN HEART JOURNAL (2018)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

sST2 Predicts Outcome in Chronic Heart Failure Beyond N-proBNP and High-Sensitivity Troponin T

Michele Emdin et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes

Finn Gustafsson et al.

EUROPEAN JOURNAL OF HEART FAILURE (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review

Elke Platz et al.

EUROPEAN JOURNAL OF HEART FAILURE (2017)

添加到收藏夹

Article Medicine, General & Internal

Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction A Randomized Clinical Trial

G. Michael Felker et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure

Yuya Matsue et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Acute Heart Failure Alternatives to Hospitalization

Reka Zsilinszka et al.

JACC-HEART FAILURE (2017)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure

Alberto Aimo et al.

JACC-HEART FAILURE (2017)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Pathophysiology and clinical evaluation of acute heart failure

Robert J. Mentz et al.

NATURE REVIEWS CARDIOLOGY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting Evidence From the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)

Naoki Okumura et al.

CIRCULATION (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients

Elke Platz et al.

EUROPEAN HEART JOURNAL (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit

Leo F. Buckley et al.

JACC-HEART FAILURE (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring

Maria R. Costanzo et al.

JACC-HEART FAILURE (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE

Jesus Alvarez-Garcia et al.

EUROPEAN JOURNAL OF HEART FAILURE (2015)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

In-hospital worsening heart failure

Javed Butler et al.

EUROPEAN JOURNAL OF HEART FAILURE (2015)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Emergency department visits for heart failure and subsequent hospitalization or observation unit admission

Saul Blecker et al.

AMERICAN HEART JOURNAL (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT

Hicham Skali et al.

EUROPEAN JOURNAL OF HEART FAILURE (2014)

添加到收藏夹

Editorial Material Medicine, General & Internal

Recognizing Worsening Chronic Heart Failure as an Entity and an End Point in Clinical Trials

Javed Butler et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

The Global Health and Economic Burden of Hospitalizations for Heart Failure Lessons Learned From Hospitalized Heart Failure Registries

Andrew P. Ambrosy et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Results of the Destination Therapy Post-Food and Drug Administration Approval Study With a Continuous Flow Left Ventricular Assist Device A Prospective Study Using the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support)

Ulrich P. Jorde et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure

John J. V. McMurray et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Burden of Acute Heart Failure on U.S. Emergency Departments

Alan B. Storrow et al.

JACC-HEART FAILURE (2014)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program Correlation With Outcomes

Marco Metra et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

添加到收藏夹

Editorial Material Cardiac & Cardiovascular Systems

Is Hospital Admission for Heart Failure Really Necessary? The Role of the Emergency Department and Observation Unit in Preventing Hospitalization and Rehospitalization

Sean P. Collins et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Is Worsening Renal Function an Ominous Prognostic Sign in Patients With Acute Heart Failure? The Role of Congestion and Its Interaction With Renal Function

Marco Metra et al.

CIRCULATION-HEART FAILURE (2012)

添加到收藏夹

Review Cardiac & Cardiovascular Systems

Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section

James L. Januzzi et al.

EUROPEAN HEART JOURNAL (2012)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Intrathoracic Impedance Monitoring, Audible Patient Alerts, and Outcome in Patients With Heart Failure

Dirk J. van Veldhuisen et al.

CIRCULATION (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification

Andrew J. Boyle et al.

JOURNAL OF HEART AND LUNG TRANSPLANTATION (2011)

添加到收藏夹

Article Medicine, General & Internal

Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial

William T. Abraham et al.

LANCET (2011)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Transition from chronic compensated to acute decompensated heart failure - Pathophysiological insights obtained from continuous monitoring of intracardiac pressures

Michael R. Zile et al.

CIRCULATION (2008)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Patterns of weight change preceding hospitalization for heart failure

Sarwat I. Chaudhry et al.

CIRCULATION (2007)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure

Scott D. Solomon et al.

CIRCULATION (2007)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: An analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

Gregg C. Fonarow et al.

AMERICAN HEART JOURNAL (2007)

添加到收藏夹

Article Medicine, General & Internal

Effects of initiating carvedilol in patients with severe chronic heart failure - Results from the COPERNICUS study

H Krum et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)

添加到收藏夹

Article Medicine, General & Internal

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

JN Cohn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.